PT - JOURNAL ARTICLE AU - Rios Coronado, Pamela E. AU - Zanetti, Daniela AU - Zhou, Jiayan AU - Naftaly, Jeffrey A. AU - Prabala, Pratima AU - Martínez Jaimes, Azalia M. AU - Farah, Elie N. AU - Fan, Xiaochen AU - Kundu, Soumya AU - Deshpande, Salil S. AU - Evergreen, Ivy AU - Kho, Pik Fang AU - Hilliard, Austin T. AU - Abramowitz, Sarah AU - Pyarajan, Saiju AU - Dochtermann, Daniel AU - Program, Million Veteran AU - Damrauer, Scott M. AU - Chang, Kyong-Mi AU - Levin, Michael G. AU - Winn, Virginia D. AU - Paşca, Anca M. AU - Plomondon, Mary E. AU - Waldo, Stephen W. AU - Tsao, Philip S. AU - Kundaje, Anshul AU - Chi, Neil C. AU - Clarke, Shoa L. AU - Red-Horse, Kristy AU - Assimes, Themistocles L. TI - <em>CXCL12</em> drives natural variation in coronary artery anatomy across diverse populations AID - 10.1101/2023.10.27.23297507 DP - 2024 Jan 01 TA - medRxiv PG - 2023.10.27.23297507 4099 - http://medrxiv.org/content/early/2024/07/05/2023.10.27.23297507.short 4100 - http://medrxiv.org/content/early/2024/07/05/2023.10.27.23297507.full AB - To efficiently distribute blood flow to cardiac muscle, the coronary artery tree must follow a specific branching pattern over the heart. How this pattern arises in humans is unknown due to the limitations of studying human heart development. Here, we leveraged a natural variation of coronary artery anatomy, known as coronary dominance, in genetic association studies to identify the first known driver of human coronary developmental patterning. Coronary dominance refers to whether the right, left, or both coronary arteries branch over the posterior left ventricle, but whether this variability is heritable and how it would be genetically regulated was completely unknown. By conducting the first large-scale, multi-ancestry genome-wide association study (GWAS) of coronary dominance in 61,043 participants of the VA Million Veteran Program, we observed moderate heritability (27.7%) with ten loci reaching genome wide significance. An exceptionally strong association mapped DNA variants to a non-coding region near the chemokine CXCL12 in both European and African ancestries, which overlapped with variants associated with coronary artery disease. Genomic analyses predicted these variants to impact CXCL12 levels, and imaging revealed dominance to develop during fetal life coincident with CXCL12 expression. Reducing Cxcl12 in mice to model the human genetics altered septal artery dominance patterns and caused coronary branches to develop away from Cxcl12 expression domains. Cxcl12 heterozygosity did not compromise overall artery coverage as seen with full deletion, but instead changed artery patterning, reminiscent of the human scenario. Together, our data support CXCL12 as a critical determinant of human coronary artery growth and patterning and lay a foundation for the utilization of developmental pathways to guide future precision ‘medical revascularization’ therapeutics.Competing Interest StatementA.K. is on the scientific advisory board of SerImmune, TensorBio and OpenTargets, and a consultant with Arcadia Science and Inari Agriculture. A.K. was a scientific co-founder of RavelBio, a paid consultant with Illumina, was on the SAB of PatchBio and owns shares in DeepGenomics, Immunai, Freenome, and Illumina. All other authors declare they have no competing interests.Funding StatementThis research is based on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration, and was supported by Veterans Administration awards I01-01BX003362. The content of this manuscript does not represent the views of the Department of Veterans Affairs or the United States Government. P.E.R.C was supported by NIH-TIMBS-T32HL094274. E.N.F was supported by NIH-T32HL007444. J.A.N was supported by NIH-T32GM007276. S.L.C was supported by NIH-CTSA KL2TR003143. K.R-H was supported by NIH-R01HL12850307 and the Howard Hughes Medical Institute. M.G.L was supported by the Doris Duke Foundation award #2023-0224 The Penn Medicine Biobank is supported by the Perelman School of Medicine at University of Pennsylvania, a gift from the Smilow family, and the National Center for Advancing Translational Sciences of the National Institutes of Health under CTSA award number UL1TR001878.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study received ethical and study protocol approval from the Veteran Affairs Central Institutional Review Board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe full summary level association statistics from each genetically inferred ancestry population association analyses in MVP from this report will be available through dbGaP, with accession number phs001672 at the time of publication in a peer reviewed journal.